FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
CF Wielenberg, JC Fostitsch, C Volz… - Nuklearmedizin …, 2024 - thieme-connect.com
Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of
treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of …
treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of …